28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project

Table 1 from study evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial

Table 2 from study evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial

Figure 1 for 28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project

Figure 2. for 28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project

Duration of hospitalization results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project